N@N

RPBC, RGDX, NSPH, QGEN, PPHM, PGNX, Biomed - Genetics Stocks 34.43% undervalued

^{Published on 2011-01-26 12:32:21 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. REDPOINT BIO CORP (OTCBB:RPBC), RESPONSE GENETICS INC (NASDAQ:RGDX), NANOSPHERE INC (NASDAQ:NSPH), QIAGEN N.V. (NASDAQ:QGEN), PEREGRINE PHARMACEUTICALS (NASDAQ:PPHM), PROGENICS PHARMACEUTICALS (NASDAQ:PGNX) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     RPBC       REDPOINT BIO CORP                   0.2            0.31           34.43% undervalued          Biomed - Genetics      
     RGDX       RESPONSE GENETICS INC               2.35           2.38           1.21% undervalued           Biomed - Genetics      
     NSPH       NANOSPHERE INC                      3.84           4.98           22.88% undervalued          Biomed - Genetics      
     QGEN       QIAGEN N.V.                         18.77          19.16          2.03% undervalued           Biomed - Genetics      
     PPHM       PEREGRINE PHARMACEUTICALS           2.44           7.23           66.26% undervalued          Biomed - Genetics      
     PGNX       PROGENICS PHARMACEUTICALS           6.04           15.46          60.92% undervalued          Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

REDPOINT BIO CORP (OTCBB:RPBC) - Redpoint Bio Corporation engages in the development of healthier foods and beverages, and new approaches for the treatment of diabetes and obesity by understanding of the biology of taste and its relationship to metabolism, satiety, and diabetes. It is developing taste modulators for the food and beverage industry to enhance sweet and savory flavors in food and beverage products, which can lead to reductions in added sugar and salt. The development of healthier and more tasteful food can contribute to enhance the overall health, since various modern diseases are related to excess dietary sugar and salt. The company is based in Ewing, New Jersey.

RESPONSE GENETICS INC (NASDAQ:RGDX) - Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suites for non-small cell lung cancer; ResponseDX: Colon test suites for colorectal cancer; and ResponseDX: Gastric test suites for gastric and gastroesophageal cancer. The companys Response DX test measures the RNA expression of ERCC1, TS, and RRM1 through reverse transcription polymerase chain reaction analysis from a patient's tumor tissue; and polymerase chain reaction analysis of DNA from the patient's sample to determine EGFR amplification, as well as BRAF, EGFR, and KRAS mutational status. It is also developing tests for other types of cancer that identify genetic profiles of tumors that recur after surgery. The company offers its products through its sales force to community based oncologists, hospitals, and physician offices. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

NANOSPHERE INC (NASDAQ:NSPH) - Nanosphere, Inc. develops, manufactures, and markets a molecular diagnostics platform, the Verigene System that enables genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests simultaneously on the same sample, as well as simplifies molecular diagnostic testing. The company develops diagnostic tests for markers, which reveal the existence of various medical conditions, including cardiovascular, respiratory, cancer, autoimmune, neurodegenerative, and other infectious diseases, as well as for pharmacogenomics. It also engages in developing and commercializing genomic and protein assays, including hyper-coagulation, warfarin metabolism, cystic fibrosis, respiratory virus panel, hemochromatosis, blood infection panel, cardiac troponin I, connective tissue, prostate specific antigen, and biomarker validation. Nanosphere intends to market its solutions for applications in the hospital-based laboratories and academic research institutions in the United States. The company is headquartered in Northbrook, Illinois.

QIAGEN N.V. (NASDAQ:QGEN) - QIAGEN N.V., through its subsidiaries, provides sample and assay technologies. Sample technologies are used to isolate and process deoxyribonucleic acid, ribonucleic acid, and proteins from biological samples, such as blood or tissue; and assay technologies are used to make such isolated bio-molecules visible. It markets approximately 500 sample and assay products, as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes, such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's primary assay technologies include the broadest panels of molecular diagnostic tests available. This panel comprises the digene HPV Test, which is regarded as a gold standard in testing for high-risk types of human papillomavirus, the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. The company markets its products through a sales force and a network of distributors principally in the Americas, Germany, Asia, and Switzerland. It has a collaboration agreement with Genome Diagnostics B.V. for development of tests for applications in prevention and personalized healthcare. QIAGEN was founded in 1986 and is headquartered in Venlo, the Netherlands.

PEREGRINE PHARMACEUTICALS (NASDAQ:PPHM) - PEREGRINE PHARMA

PROGENICS PHARMACEUTICALS (NASDAQ:PGNX) - Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company offers RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation in advanced illness patients receiving palliative care. It is also conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells, as well as in blood vessels supplying other solid tumors. In addition, the company is developing therapeutic vaccines designed to stimulate an immune response to PSMA; PRO 140, a viral-entry inhibitor for human immunodeficiency virus (HIV), which is in Phase II clinical testing; and novel multiplex PI3-Kinase inhibitors to combat aggressive forms of cancer. Additionally, it engages in researching a prophylactic vaccine for HIV infection; and candidates that are HCV-entry inhibitors. The company was founded in 1986 and is based in Tarrytown, New York.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net